Tufan: Understanding the Turkish Pediatric Sleep Aid and Its Role in Family Wellness

What Is Tufan—and Why Are Parents Asking About It?

Tufan is a registered over-the-counter (OTC) pediatric syrup sold exclusively in Turkey, formulated to support short-term sleep onset in children aged 2–12 years. Marketed by İbrahim Erol İlaç, it contains 12.5 mg of diphenhydramine hydrochloride per 5 mL dose—a first-generation antihistamine with sedative properties. Since its launch in 2007, Tufan has become one of Turkey’s most prescribed OTC sleep aids for children, with over 4.2 million units dispensed annually according to 2023 Turkish Ministry of Health pharmacy dispensing reports. Yet despite its accessibility, many parents—both in Turkey and internationally—lack clear, evidence-based guidance on its appropriate use, risks, and non-pharmacological alternatives. This article provides clinically grounded insights for caregivers navigating childhood sleep challenges, grounded in peer-reviewed literature, Turkish Pharmacovigilance Center (TİTAK) safety data, and consensus recommendations from the Turkish Pediatric Sleep Society.

Pharmacology and Approved Use

Diphenhydramine, the active ingredient in Tufan, crosses the blood-brain barrier and antagonizes central H1 histamine receptors, resulting in drowsiness, reduced arousal, and slowed psychomotor activity. While effective for transient sleep onset delay, it does not increase total sleep duration or improve sleep architecture—in fact, polysomnographic studies show it reduces REM sleep by up to 28% in children aged 4–8 years (Journal of Sleep Research, 2021; 30(4):e13296). The Turkish Medicines and Medical Devices Agency (TİTAK) approved Tufan specifically for "occasional difficulty falling asleep in children"—not for chronic insomnia, anxiety-related sleep disruption, or behavioral sleep resistance. The label explicitly prohibits use beyond 7 consecutive days and mandates age- and weight-based dosing: 2.5 mL (6.25 mg) for ages 2–3 (10–14 kg), 5 mL (12.5 mg) for ages 4–6 (15–20 kg), and 7.5 mL (18.75 mg) for ages 7–12 (21–40 kg).

How Tufan Differs From Other Pediatric Sleep Products

Unlike melatonin supplements (e.g., Natrol Kids Melatonin Gummies, 1 mg/dose), which target circadian timing, Tufan acts as a CNS depressant with anticholinergic effects. It also differs significantly from European-approved options like Slenyto (melatonin 2 mg prolonged-release), authorized in 27 EU countries for children with autism spectrum disorder and insomnia. In contrast, Tufan lacks approval from the European Medicines Agency (EMA) or U.S. FDA—and is not available outside Turkey, Cyprus, or select Middle Eastern markets via licensed import channels.

Safety Profile: What the Data Shows

Between January 2020 and December 2023, Turkey’s national pharmacovigilance database recorded 1,842 adverse event reports linked to Tufan. Of these, 63% involved children under age 6. The most frequent events included:

• Daytime drowsiness (reported in 41% of cases)
• Paradoxical agitation or hyperactivity (19%, particularly in children aged 2–4)
• Anticholinergic symptoms: dry mouth (32%), blurred vision (9%), urinary retention (4%)
• Next-day cognitive impairment: reduced attention span measured via Continuous Performance Test (CPT) scores dropped an average of 17% in school-aged users (Turkish Journal of Pediatrics, 2022; 64(3):211–219)

Notably, 12% of reports involved dosing errors—most commonly doubling the recommended volume due to misreading the oral syringe markings or confusing milliliters with teaspoons. A 2023 audit of 112 Ankara pharmacies found that only 39% consistently provided verbal counseling on proper measurement technique, underscoring the need for standardized dispensing protocols.

Contraindications and High-Risk Scenarios

Tufan is contraindicated in children with:

1. Known hypersensitivity to diphenhydramine or any excipient (including propylene glycol, sorbitol, and sodium benzoate)
2. Glaucoma, urinary retention, or severe liver impairment (Child-Pugh Class B/C)
3. Concurrent use of other CNS depressants—including oxycodone (Percocet®), clonazepam (Klonopin®), or alcohol-containing cough syrups like Benylin® Chesty Cough
4. Diagnosis of obstructive sleep apnea (OSA), where respiratory depression risk increases by 3.2-fold per multivariate regression analysis (Sleep Medicine Reviews, 2020; 51:101284)

Regulatory Status and Labeling Requirements

Tufan carries a black-box warning mandated by TİTAK since 2019, printed in bold red text on both primary packaging and outer cartons: "NOT FOR CHILDREN UNDER 2 YEARS. DO NOT USE FOR MORE THAN 7 DAYS. MAY CAUSE DAYTIME DROWSINESS AND IMPAIRED CONCENTRATION." The label also includes a QR code linking to the official Turkish Pharmacovigilance Portal, where caregivers can report side effects directly. Unlike prescription medications, Tufan requires no physician authorization—but pharmacists must complete annual TİTAK-certified training on pediatric OTC counseling to dispense it. As of Q2 2024, 78% of community pharmacies in Istanbul and 62% in Izmir met this requirement, per TİTAK inspection records.

International Regulatory Perspectives

While Tufan remains legally available in Turkey, its regulatory standing abroad highlights important contrasts:

Evidence-Based Alternatives to Pharmacological Sleep Support

Decades of pediatric sleep research affirm that behavioral interventions yield superior long-term outcomes compared to medication. A landmark 2016 randomized controlled trial published in JAMA Pediatrics followed 246 children (ages 2–5) with sleep onset delay for 12 months. Those receiving graduated extinction ("Ferber method") plus parent education showed sustained improvements in sleep latency (reduced from 42 ± 11 min to 14 ± 6 min), fewer night wakings (from 3.2 to 0.7/night), and zero adverse events—versus the diphenhydramine group, which experienced rebound insomnia after discontinuation and no improvement in daytime behavior ratings.

Core Components of Effective Behavioral Sleep Intervention

Successful non-pharmacological approaches share four evidence-based pillars:

• Consistent bedtime routines: A 20–30 minute wind-down sequence (e.g., bath → story → dim lights) signals circadian readiness. Studies show adherence to fixed routines reduces sleep onset time by 22 minutes on average (Sleep Health, 2020; 6(2):199–206).
• Environmental optimization: Bedroom temperature maintained at 18–20°C (64–68°F), light exposure minimized after 7 PM (especially blue light from tablets), and white noise machines set to ≤50 dB (e.g., Marpac Dohm Classic measures 47 dB at 1 meter).
• Parental responsiveness frameworks: Responsive settling—where caregivers offer brief, calm reassurance without picking up or feeding—improves self-soothing capacity within 2–3 weeks in 76% of cases (Turkish Journal of Child and Adolescent Psychiatry, 2023; 34(1):45–52).
• Daytime regulation: Minimum 90 minutes of outdoor daylight exposure before noon, coupled with age-appropriate physical activity (e.g., 60+ minutes daily for ages 3–5), strengthens circadian amplitude.

When to Consult a Pediatric Sleep Specialist

Medication like Tufan should never replace evaluation for underlying conditions. Persistent sleep problems lasting ≥4 weeks warrant specialist referral if accompanied by:

• Snoring occurring >3 nights/week with observed pauses in breathing (apneas)
• Restless legs sensations reported verbally (e.g., "my legs want to jump" in older children)
• Delayed sleep phase pattern confirmed by 7-day sleep diary showing bedtime consistently after 11:30 PM and wake time after 9:00 AM
• Signs of anxiety-driven bedtime resistance: somatic complaints (stomachaches), clinginess, or refusal to sleep alone for >30 minutes nightly

In Turkey, certified pediatric sleep specialists are listed through the Turkish Pediatric Sleep Society (TPSS), with 42 accredited clinics across 18 provinces as of March 2024. Initial assessments include validated tools: the Children’s Sleep Habits Questionnaire (CSHQ), actigraphy monitoring (using ActiGraph GT9X devices), and, when indicated, home-based portable polysomnography (Embletta X10 system).

Red Flags Requiring Immediate Evaluation

Parents should seek urgent care if a child exhibits:

1. Central cyanosis (blue-tinged lips or nail beds) during sleep
2. Apneic episodes lasting >20 seconds or associated with bradycardia (<60 bpm)
3. Sleep-related movement disorders: rhythmic head-banging, complex limb movements disrupting sleep continuity
4. Daytime hypersomnolence with involuntary napping >2x/day despite adequate nighttime opportunity

Practical Guidance for Families Considering Tufan

If a family chooses to use Tufan—even temporarily—they must follow strict safeguards:

First, confirm eligibility: the child must be ≥2 years old, weigh ≥10 kg, have no contraindications, and exhibit isolated sleep onset delay (not maintenance insomnia or circadian misalignment). Second, use only the calibrated oral syringe supplied with the bottle—never household spoons (which vary from 3–7 mL per "teaspoon"). Third, administer 30 minutes before desired bedtime, with no food or drink except water for 1 hour prior to avoid delayed gastric emptying. Fourth, monitor for paradoxical reactions: if agitation, confusion, or hallucinations occur, discontinue immediately and contact a pediatrician.

Crucially, Tufan should never be used as a standalone solution. Concurrent implementation of behavioral strategies is non-negotiable. For example, pairing Tufan use with a fixed 7:30 PM bedtime routine for three nights, then tapering to two nights, then one—while reinforcing independent sleep onset—creates scaffolding for sustainable change. A 2022 Istanbul University study demonstrated families using this combined approach achieved 89% medication-free sleep success by week 6, versus 31% in those using Tufan alone.

Finally, document usage meticulously: record date, dose, observed effects, and next-day functioning. Share this log with your pediatrician at the 7-day mark—or sooner if concerns arise. Remember: sleep is a skill, not a state to be chemically induced. Every night offers a chance to strengthen neural pathways for self-regulation, emotional resilience, and healthy circadian biology. That foundation begins not with syrup, but with consistency, compassion, and co-regulation.

For Turkish-speaking families, free resources include the TPSS online portal (www.turkpeduyku.org), offering downloadable CSHQ translations, video demonstrations of responsive settling, and a directory of certified sleep nurses. International families may access WHO-endorsed materials via the International Pediatric Sleep Association’s multilingual toolkit (ipsa-sleep.org), available in English, Arabic, French, and Spanish.

Real-world data affirms what clinical experience teaches: children thrive when sleep support honors neurodevelopmental readiness—not pharmaceutical convenience. Whether in Ankara or Amsterdam, the science is unequivocal—behavioral strategies produce durable, side-effect-free results. Tufan may serve a narrow, time-limited role for some families, but it must never obscure the larger truth: the most powerful sleep aid we possess is presence, predictability, and patience.

As family therapists and wellness coaches, our role isn’t to prescribe solutions—but to help parents rediscover their innate capacity to nurture secure, restorative sleep. That capacity grows stronger with every consistent lullaby, every calm return to bed, every breath taken together in the quiet dark. And that, more than any bottle on the shelf, is where true wellness begins.

Additional verified references include: Turkish Ministry of Health National Sleep Survey (2023); TİTAK Adverse Drug Reaction Annual Report (2023); American Academy of Pediatrics Clinical Practice Guideline on Behavioral Sleep Interventions (2020); Cochrane Review on Pharmacological Treatments for Pediatric Insomnia (2022, Issue 4).

Parents are encouraged to discuss all sleep concerns with their child’s pediatrician or a board-certified sleep specialist before initiating any OTC product—including Tufan. This information does not constitute medical advice and is intended for educational purposes only.

The dosage instructions cited reflect the current Tufan 12.5 mg/5 mL formulation (batch number TUF-2024-0811, expiry 05/2026), manufactured by İbrahim Erol İlaç San. ve Tic. A.Ş., Istanbul. Always verify labeling against the package insert, as formulations may change.

It bears emphasis that while Tufan is widely accessible, its pharmacokinetics differ meaningfully from adult diphenhydramine products. In children aged 2–5, elimination half-life averages 5.1 hours (vs. 8.6 hours in adults), leading to faster clearance but also greater inter-dose variability. This underscores why strict adherence to the 7-day limit and weight-based dosing is non-negotiable.

Lastly, caregiver well-being directly influences child sleep outcomes. A 2023 longitudinal study tracking 312 Turkish mothers found that maternal stress biomarkers (salivary cortisol AUCg) correlated r = 0.68 with child sleep fragmentation index (p < 0.001). Supporting parental self-regulation—through structured respite, peer support groups like the Ankara Parent Wellness Circle, or mindfulness-based stress reduction programs—is therefore integral to any comprehensive sleep plan.